Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

COMT inhibitor disclosed by Roche

June 21, 1996

Taro's anticonvulsant drug undergoes development

June 21, 1996

Pierre Fabre describes 5-HT1 receptor ligands

June 21, 1996

FDA approves Organon's Remeron

June 21, 1996

RPR describes RPR-107880 synthesis

June 21, 1996

Cypros conferred SBIR grant to develop CPC-111 prodrugs

June 14, 1996

Activase cleared by FDA for ischemic stroke

June 14, 1996

More glutamate antagonists from NeuroSearch

June 14, 1996

Novo Nordisk synthesizes AMPA antagonists

June 14, 1996

Glutamate antagonists reported by BASF

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...